Abstract
This investigation examines the clinical response to long-term treatment of the diabetic syndrome of limited joint mobility (LJM) using an aldose reductase inhibitor (ARI) in comparison to historical controls, and proposes a potential role of aldose reductase (AR) genotype and expression in the clinical response to ARI. Clinical parameters, including quantitative hand movement and electromyogram, were followed over a decade of continuous ARI treatment with sorbinil (400 mg/day) in two patients with insulin-dependent diabetes mellitus (IDDM) and severe compromising LJM, and compared to the published 10-year prospective investigation of untreated IDDM diabetic patients with LJM. Both subjects were homozygous for the Z-2 AR allele (A-C)23 that has been linked with microvascular complications of DM. Cellular AR mRNA/beta-actin ratios for both treated patients while on ARI therapy were approximately one-half the value observed in untreated patients with the complications of nephropathy or neuropathy. This is the longest reported experience of ARI intervention for any diabetic complication, documenting sustained correction of LJM, lack of side effects, and a potential molecular basis for the therapeutic response.
References
Oct 1, 1975·Diabetes·C R HamlinJ H Luschin
Feb 1, 1977·Biopolymers·S NomuraE Baer
Nov 26, 1992·Nature·W A BorderE Ruoslahti
Apr 1, 1992·Diabetes Care·A L RosenbloomJ A Truglia
Mar 11, 1992·The American Journal of Physiology·F L SmardoA Garcia-Perez
Jul 3, 1992·Science·D K WilsonF A Quiocho
Jul 1, 1992·The Journal of Clinical Investigation·W A Border, E Ruoslahti
Nov 1, 1991·Diabetes·A GhaharyL J Murphy
Oct 1, 1990·The Journal of Clinical Investigation·C BondyP F Kador
Mar 1, 1989·Mechanisms of Ageing and Development·W L SibbittD L Vander Jagt
Sep 1, 1985·Diabetic Medicine : a Journal of the British Diabetic Association·M Mengistu, J Abdulkadir
May 1, 1986·British Journal of Rheumatology·B PalI D Griffiths
Mar 8, 1985·JAMA : the Journal of the American Medical Association·R P EatonA Harsh
Feb 1, 1986·Annals of the Rheumatic Diseases·H S StarkmanJ S Soeldner
Apr 19, 1973·The New England Journal of Medicine·K H Gabbay
Nov 1, 1971·Metabolism: Clinical and Experimental·Y JungT S Danowski
Mar 1, 1984·Diabetes Care·B A BuckinghamA Castellano
Feb 1, 1980·European Journal of Clinical Investigation·S BazinA Delaunay
Jan 1, 1995·The Journal of Hand Surgery·M ChammasY Allieu
Jan 1, 1995·Diabetologia·R I DorinP G Zager
Mar 1, 1995·Diabetologia·T YamaokaY Kokai
Jul 1, 1995·Diabetes·B C KoS S Chung
Aug 1, 1994·Journal of Internal Medicine·P E ArkkilaJ S Viikari
Mar 1, 1994·Diabetologia·C NishimuraT Tanimoto
Nov 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·D R McCanceL Kennedy
Apr 1, 1996·Diabetologia·R P EatonR H Griffey
Citations
May 5, 2004·Best Practice & Research. Clinical Rheumatology·Perttu E T Arkkila, Jean-Francois Gautier
Jul 11, 2006·Clinics in Dermatology·Intekhab Ahmed, Barry Goldstein
Jan 5, 2001·Expert Opinion on Investigational Drugs·P J Oates, B L Mylari
Aug 13, 2011·Diabetes Research and Clinical Practice·Hisham Y Al-MatubsiMaher Salim
Jan 2, 2007·Clinical Orthopaedics and Related Research·Odette LaneuvilleGuy Trudel
Dec 18, 2004·Current Opinion in Rheumatology·Dana Jacobs-Kosmin, Raphael J DeHoratius